[{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","commit":"e03f56897d","date":"2026-09-10","author":"Jude Gomila","message":"Primary source links (FDA label via DailyMed) for thirty approved products that had none","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"links","after":"[{ label: \"FDA label (DailyMed)\", url: \"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Adagrasib\" }]"}]},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","commit":"57b67248b1","date":"2026-09-10","author":"Jude Gomila","message":"Improvements batch B: clinician power tools","file":"src/data/interactions.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"class"},{"field":"props"},{"field":"management"},{"field":"pairs"},{"field":"source"}]},{"id":"adagrasib","kind":"drug","name":"Adagrasib","route":"/drugs/adagrasib/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/drugs.ts","type":"changed","fields":[{"field":"tldr","before":"\"The second KRAS G12C inhibitor, with a long half-life and brain penetration, approved in lung and colorectal cancer.\"","after":"\"Adagrasib was the second KRAS G12C inhibitor, with a long half-life and brain penetration, and is approved in lung and colorectal cancer.\""}]}]